Todd Aguilera: We must educate and rethink
Todd Aguilera, Radiation Oncologist at UT Southwestern Medical Center, recently tweeted:
“We must educate and rethink, 18 years since the last FDA approval of a drug in combo with RT. Pembro+CRT in Cervical CA! Today at the National Cancer Institute Dr. Kiran from Johnson and Johnson spent several slides talking about our own Dr. Nina Niu Sanford’s recent Journal of Clinical Oncology paper regarding disparities in RT trial expectations.
Hopefully, last week’s approval is one of several to come! Why this disparity? Is it bias or $$$ to study and earn once an approval? Let’s work with industry and cooperative groups to keep study of RT and RT combo same as another new cancer treatment. Especially as RT improves aspects of life in metastatic disease.”
Source: Todd Aguilera/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023